Table 1 Baseline characteristics of the studies in the meta-analysis
From: Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
Studies (reference) | Year | Country | Treatment | Sample size (male, n) | Mean/median ages (years) | Vascular invasion (yes) | Differentiation (I,II/III,IV,n) |
|---|---|---|---|---|---|---|---|
Shirakawal [18] | 2009 | Japan | SR | 107(85) | 63.6/60.2 | 57 | 12/95 |
Yorita [19] | 2010 | Japan | SR | 194(142) | NA | 108 | 179/15 |
Su [20] | 2012 | China | SR | 61(55) | 48.0 | NA | NA |
Yu [21] | 2012 | Taiwan | SR | 100(90) | 51.39 | 23 | NA |
Wang [23] | 2012 | China | LT | 31(29) | 49 | 16 | 6/25 |
Chen [24] | 2013 | Japan | SR | 55(36) | 65.5 /63.5 | NA | NA |
Fu [25] | 2013 | China | SR | 160(140) | 50.2 | 30 | 123/37 |
Liang [26] | 2013 | China | SR | 362(324) | 43-50 | 53 | NA |
Studies (Reference) | Tumor stage (I, II/ III, IV, n) | Follow- up Mean/ median (months) | Outcome indexes | Multi- variate analysis | Patients with High GPC3 | Study quality (Points) | "high" GPC3 cut- off level |
Shirakawal [18] | 92/15 | 42 | OS/DFS | Yes | 87 | 8/9 | >10 % |
Yorita [19] | 82/112 | 31.2 | OS/DFS | Yes | 97 | 7/9 | ≥20 % |
Su [20] | 45/16 | NA | OS/DFS | Yes | 32 | 5/9 | >10 % |
Yu [21] | NA | 66.5 | DFS | NA | NA | 5/9 | +3* |
Wang [23] | 12/19 | 24 | DFS | NA | 20 | 5/9 | >10 % |
Chen [24] | NA | 66 | OS/DFS | yes | 28 | 6/9 | >10 % |
Fu [25] | NA | 34.5 | OS/DFS | yes | 109 | 8/9 | >25 % |
Liang [26] | NA | 34.5 | OS | NA | 228 | 6/9 | >0 % |
Studies (Reference) | Antibody type | Detection method | Evaluation method | GPC3 staining | |||
Shirakawal [18] | Mouse Monoclonal antibody | IHC | Positive area | Cytoplasm membrane | |||
Yorita [19] | Monoclonal antibody | IHC: Histofine Her2 kit | Positive area | Cytoplasm membrane | |||
Su [20] | Mouse Monoclonal antibody | IHC: Chemmate EnVision/Mo&Rb detection kit | Positive area and intensity | Cytoplasm membrane | |||
Yu [21] | NA | IHC | NA | Cytoplasm membrane | |||
Wang [23] | Monoclonal antibody | IHC | Positive area | Cytoplasm membrane | |||
Chen [24] | Rabbit monoclonal antibody | IHC | Positive area | cytoplasm peri- canalicular | |||
Fu [25] | Mouse Monoclonal antibody | IHC | Percentage of positive cells | Cytoplasm membrane | |||
Liang [26] | NA | IHC: two-step protocol (DakoCytomation, Glostrup, Denmar) | TMAJ Image application | Cytoplasm membrane | |||